Pharma firms use low-cost telehealth visits to steer patients toward their own drugs

Pharmaceutical companies have found a way to sell prescription drugs that looks like a doctor's visit and functions like a coupon.

The question is whether it is actually either.

A STAT News investigation published Thursday examined how Eli Lilly, Pfizer, and other drugmakers have built direct-to-consumer telehealth platforms that route patients toward specific medications at conversion rates that would make a sales department weep: 100 percent of patients who visited one of Eli Lilly's partnered telehealth providers received a prescription. Eighty-five percent for Pfizer's equivalent program. Eli Lilly and Pfizer spent up to $3 million combined building these arrangements. Eli Lilly paid $942,500 alone in three-year contract fees to its telehealth partners.

This is not a bug. It is the product.

The mechanism has been sitting in plain sight for months. Senate investigators examined it. A January 2026 guidance document flagged it. STAT News documented it in detail. What is new is the infrastructure being built to scale it.

On January 27, 2026, the Office of Inspector General issued a Special Advisory Bulletin on how the federal Anti-Kickback Statute applies to direct-to-consumer prescription drug sales. Law firms scrambled to analyze it. Venable LLP's breakdown captured the key detail in its title: the bulletin covers drugmakers selling directly to consumers, but does not address arrangements involving physicians, pharmacies, pharmacy benefit managers, telemedicine vendors, marketers, or other third parties.

The OIG wrote a document about kickbacks in pharma DTC, then explicitly declined to cover the third parties that make pharma DTC work. That is not an oversight. That is a sentence.

TrumpRx, which launched February 5, 2026, is the infrastructure designed to scale what the Eli Lilly and Pfizer pilots demonstrated. Advertised as a transformative healthcare initiative, the platform was built to route patients through sponsored telehealth visits toward sponsored drugs. The arrangement was flagged as a conflict of interest before the platform ever launched.

One detail that has not aged quietly: Donald Trump Jr. joined the board of BlinkRx, a prescription affordability platform, in February 2025. BlinkRx operates in this same space. A Senate letter flagged the involvement of the President's son in a platform built to steer patients toward specific drugs while that same administration stood up TrumpRx. The letter described this as deserving scrutiny that has not, to date, produced a satisfactory answer.

The Addyi arrangement is the proof of concept that makes the abstract concrete.

When Sprout Pharmaceuticals re-launched Addyi — a drug for hypoactive sexual desire disorder, a condition marked by persistently low sexual desire in women — the company offered telehealth consultations through a platform called Prescribery. Sprout's CEO Ross Pope described the arrangement with plainness that is either refreshing or alarming, depending on your relationship to the concept of a medical consultation. "We give them the coupon codes that they can use, and they get to market it to drive additional business," he told STAT News.

Prescribery's Addyi page is not a neutral healthcare marketplace. It is an Addyi sales funnel with a medical license. Use the code, get a low-cost visit. The code is provided by Sprout. The visit is conducted by a prescriber who has been, in effect, selected and funded by Sprout. The outcome is a prescription for Addyi. The current price on Prescribery's Addyi page is $15; promotional pricing changes, and the mechanism does not depend on any single price point.

Daniel Eisenkraft Klein, a researcher at PORTAL, Brigham and Women's Hospital and Harvard Medical School who has studied pharma DTC practices, put it plainly in the STAT News report: "These discount structures are one more piece of the same puzzle. It's this big financial architecture that's every step of the way designed to move patients toward the specific drug cheaply and quickly."

The Senate investigation documented that architecture in full. What the OIG bulletin made clear is that the federal Anti-Kickback Statute does not currently reach the middlemen who execute it. Physicians cannot receive bounties for prescriptions. Pharmacies cannot receive kickbacks for fills. But if the payment is for the visit, not the prescription, and the visit is sponsored by the drugmaker, and the coupon codes that fund it are distributed by the drugmaker, and the entire experience is designed around a single medication. That is, apparently, fine.

The OIG bulletin signaled that pharmaceutical companies selling DTC are in the crosshairs. The infrastructure they use to do so — the telehealth platforms, the marketers, the affiliated pharmacies — remains, for now, unmolested. Whether this gap is deliberate, meaning Congress needs to act, or a precursor to future OIG action, is the unresolved question at the center of this arrangement.

If that gap closes, pharma will adapt. They always do. But the template is live, documented, and producing near-perfect prescription rates. The next time someone offers you a low-cost telehealth visit, it is reasonable to ask who paid for the doctor's time, and what drug they hoped you'd leave with.

The visit is not the product. The prescription is.